(AGIO) - Earnings & Price History

AGIO: - 47.24, $2.28B, -1.32 (-2.72%)

Sector: Healthcare - Industry: Biotechnology

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The companys product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical trials for the treatment of hematologic malignancies, as well as Phase I clinical trial for treating solid tumors; and AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatm

Past AGIO reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2014-11-07BMOAgios Pharmact-0.520.172.0683.0984.8970.3984.912.17%-15.11%-13.27%1.88M
2014-08-07BMOAgios Pharmact-0.47-0.5437.137.5137.6536.5439.950.37%-1.46%-1.09%250.70K
2014-05-08BMOAgios Pharmact-0.37-0.3936.7940.7839.5136.0140.64-3.11%▲-6.88%-9.78%558.70K
2014-03-06BMOAgios Pharmact-0.34-0.439.9331.6432.0830.5142.921.39%24.47%26.20%1.12M
2013-11-07BMOAgios Pharmact-0.28-0.4719.4622221922.4-11.55%-11.55%382.70K

Login | Register
Wednesday May 24, 2017   EST
Enter a Ticker:

Economic Calendar

MBA Mortgage Applications 7:00 AM ET FHFA House Price Index 9:00 AM ET Existing Home Sales 10:00 AM ET EIA Petroleum Status Report 10:30 AM ET 2-Yr FRN Note Auction 11:30 AM ET 5-Yr Note Auction 1:00 PM ET FOMC Minutes 2:00 PM ET Robert Kaplan Speaks 6:00 PM ET Neel Kashkari Speaks 6:30 PM ET Charles Evans Speaks 9:25 PM ET  

AAII Sentiment Survey

BULL^ neut ^ BEAR


index chart
index color